Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ: NAMSW )

7.510 +0.960 (+14.66%)
Streaming Delayed Price Updated: 2:22 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,494
Open 7.600
Bid (Size) 3.000 (1)
Ask (Size) 10.00 (1)
Prev. Close 6.550
Today's Range 7.460 - 8.500
52wk Range 0.9900 - 14.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Performance

YTD
+146.23%
+146.23%
1 Month
-20.53%
-20.53%
3 Month
-16.56%
-16.56%
6 Month
-14.47%
-14.47%
1 Year
+266.34%
+266.34%

More News

Read More
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces 2024 Strategic Priorities
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.